Alrizomadlin may restore efficacy of PD-1 blockade in immunotherapy-resistant tumors

301560

Sumary of Alrizomadlin may restore efficacy of PD-1 blockade in immunotherapy-resistant tumors:

  • Use of alrizomadlin with pembrolizumab appeared to restore the antitumor effects of the anti-PD-1 antibody among patients with melanoma resistant to or intolerant of immunotherapy, according to phase 2 study results..
  • The findings, presented during the virtual ASCO Annual Meeting, also showed early antitumor activity among patients with malignant peripheral nerve sheath tumor and liposarcoma..
  • Alrizomadlin, a small-molecule MDM2-p53 antagonist, restores TP53 function and is a host immunomodulator and regulator of tumor immune escape mechanism, leading to enhanced T-cell mediated antitumor immunity..
  • “Also, research evaluating whether MDM2 inhibitors somehow reprogrammed T cells showed reprogramming of STAT5 in T cells by MDM2 ultimately led to some antitumoral immune responses in preclinical models,”.
  • 15 patients with immunotherapy-resistant non-small cell lung cancer and 10 patients with STK11-mutated lung adenocarcinoma;…

Want to know more click here go to source.

From -
Close
Generic selectors
Exact matches only
Search in title
Search in content

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close